Published in Br J Pharmacol on October 09, 2006
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res (2011) 2.41
Principles of safety pharmacology. Br J Pharmacol (2008) 1.27
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol (2008) 1.26
Effect of cleistanthin A and B on adrenergic and cholinergic receptors. Pharmacogn Mag (2011) 1.20
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov (2016) 1.01
Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol (2008) 0.97
In vitro models of proarrhythmia. Br J Pharmacol (2008) 0.95
Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. Br J Pharmacol (2009) 0.92
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br J Pharmacol (2012) 0.91
International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol (2008) 0.87
Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. Sci Adv (2015) 0.85
On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Sci Rep (2014) 0.81
Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits. PLoS One (2014) 0.77
Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes. Pharmacol Res Perspect (2014) 0.77
A phenotypic in vitro model for the main determinants of human whole heart function. Biomaterials (2015) 0.76
Sensitivity of rabbit ventricular action potential and Ca²⁺ dynamics to small variations in membrane currents and ion diffusion coefficients. Biomed Res Int (2013) 0.75
Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers. Clin Pharmacol Drug Dev (2014) 0.75
Human ex-vivo action potential model for pro-arrhythmia risk assessment. J Pharmacol Toxicol Methods (2016) 0.75
Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Front Physiol (2017) 0.75
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86
Diagnostic criteria for the long QT syndrome. An update. Circulation (1993) 4.48
Drug induced QT prolongation and torsades de pointes. Heart (2003) 3.97
Quinolones: a comprehensive review. Am Fam Physician (2002) 3.12
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J (2005) 2.24
Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol (2002) 2.19
Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc Res (1988) 2.12
Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 2.11
Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm (2005) 2.07
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation (1996) 1.79
Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol (2003) 1.71
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther (2002) 1.39
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol (2001) 1.37
Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther (2006) 1.30
Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation (2004) 1.20
Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel (2002) 1.17
New Generation Antipsychotic Drugs and QTc Interval Prolongation. Prim Care Companion J Clin Psychiatry (2003) 1.13
Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol (2005) 1.11
Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol (2004) 1.08
Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol (2003) 1.05
Quinidine. N Engl J Med (1998) 1.03
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol (2005) 1.02
Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods (2005) 1.02
Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol (2005) 0.95
Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol (2005) 0.93
Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol (1998) 0.93
Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Saf (1991) 0.92
Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol (2003) 0.90
Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther (1993) 0.89
Computer aided development of antiarrhythmic agents with class IIIa properties. J Cardiovasc Electrophysiol (1994) 0.89
Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf (2005) 0.87
Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther (2003) 0.87
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol (2004) 0.86
Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.86
Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. Cardiovasc Res (1988) 0.85
Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol (2004) 0.81
Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis (2001) 0.80
Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes. J Pharmacol Exp Ther (1995) 0.80
Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. Heart Rhythm (2005) 0.78
Induction of TU abnormalities in patients with torsades de pointes. Ann N Y Acad Sci (1992) 0.78
Fatal torsade de pointes following jaundice in a patient treated with disopyramide. Postgrad Med J (1989) 0.78
Azimilide inhibits multiple cardiac potassium currents in human atrial myocytes. J Cardiovasc Pharmacol Ther (2002) 0.78
Pirmenol inhibits muscarinic acetylcholine receptor-operated K+ current in the guinea pig heart. Eur J Pharmacol (1997) 0.77
A 3,4-diaminopyridine-insensitive, Ca(2+)-independent transient outward K+ current in cardiac ventricular myocytes. Am J Physiol (1994) 0.77
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol (2010) 2.23
A T-type Ca2+ current underlies low-threshold Ca2+ potentials in cells of the cat and rat lateral geniculate nucleus. J Physiol (1989) 2.02
Sex-reversed mice: XX and XO males. Cytogenetics (1971) 1.76
Two inward currents and the transformation of low-frequency oscillations of rat and cat thalamocortical cells. J Physiol (1991) 1.63
Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol (1995) 1.57
Anion selectivity and block of the small-conductance chloride channel on pancreatic duct cells. Am J Physiol (1990) 1.53
The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem (1998) 1.47
Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation. Physiol Genomics (2001) 1.42
Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res (1998) 1.32
Salmonella efficiently enter and survive within cultured CD11c+ dendritic cells initiating cytokine expression. Eur J Immunol (1999) 1.31
Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. Am J Physiol (1999) 1.27
Gene expression in space. Nat Med (1999) 1.27
Controlling elements in the mouse X-chromosome. I. Interaction with the X-linked genes. Genet Res (1969) 1.20
An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am J Physiol Heart Circ Physiol (2011) 1.20
Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods (2006) 1.19
Nuclear factor kappa B mediates lipopolysaccharide-induced inflammation in the urinary bladder. J Urol (2000) 1.15
Identification of rat yolk sac target protein of teratogenic antibodies, gp280, as intrinsic factor-cobalamin receptor. J Clin Invest (1997) 1.11
Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol (1995) 1.10
Genetic intersexuality in goats. J Reprod Fertil Suppl (1969) 1.10
Permeability properties of the mammalian bladder apical membrane. Am J Physiol (1994) 1.08
Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol (2008) 1.07
On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex. Br J Pharmacol (2011) 1.07
Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla. J Biol Chem (1994) 1.06
Ethyl methanesulfonate-induced chromosome breakage in the mouse. Mutat Res (1969) 1.06
AQP2 is a substrate for endogenous PP2B activity within an inner medullary AKAP-signaling complex. Am J Physiol Renal Physiol (2001) 1.06
Select de novo gene and protein expression during renal epithelial cell culture in rotating wall vessels is shear stress dependent. J Membr Biol (1999) 1.05
Controlling elements in the mouse X-chromosome. II. Location in the linkage map. Genet Res (1970) 1.04
Myeloma light chains are ligands for cubilin (gp280). Am J Physiol (1998) 1.03
LPS-sensory peptide communication in experimental cystitis. Am J Physiol Renal Physiol (2002) 1.01
Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. J Pharmacol Toxicol Methods (2007) 1.00
Control of biliary phospholipid secretion. Effect of continuous and discontinuous infusion of taurocholate on biliary phospholipid secretion. Biochem J (1986) 0.98
Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. Am J Pathol (2000) 0.97
Lung oedema--microscopic detection. J Appl Toxicol (1984) 0.95
In vitro models of proarrhythmia. Br J Pharmacol (2008) 0.95
Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. Br J Pharmacol (2009) 0.93
Rat kidney papilla contains abundant synaptobrevin protein that participates in the fusion of antidiuretic hormone-regulated water channel-containing endosomes in vitro. Proc Natl Acad Sci U S A (1995) 0.93
hERG subunit composition determines differential drug sensitivity. Br J Pharmacol (2011) 0.90
Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan. Toxicol Pathol (2010) 0.88
Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice. Physiol Genomics (2001) 0.88
Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicol Appl Pharmacol (2012) 0.86
Renin-angiotensin-aldosterone system in nephrotic syndrome. Am J Kidney Dis (1984) 0.86
The effect of nedocromil sodium on the isolated rabbit vagus nerve. Eur J Pharmacol (1992) 0.84
Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. J Pharmacol Toxicol Methods (2009) 0.84
Modulation of vasopressin-elicited water transport by trafficking of aquaporin2-containing vesicles. Annu Rev Physiol (1999) 0.83
Intrarenal and subcellular localization of rat CLC5. Am J Physiol (1998) 0.83
Differential effects of two NMDA receptor antagonists on cognitive-behavioral development in nonhuman primates I. Neurotoxicol Teratol (2001) 0.83
Mechanism of natriuresis during intrarenal infusion of prostaglandins. Am J Physiol (1984) 0.83
Validation of the use of zebrafish larvae in visual safety assessment. J Pharmacol Toxicol Methods (2008) 0.82
Differential effects of two NMDA receptor antagonists on cognitive--behavioral performance in young nonhuman primates II. Neurotoxicol Teratol (2001) 0.81
Induction and progression of cholangiofibrosis in rat liver injured by oral administration of furan. Toxicol Pathol (2010) 0.81
An intersex goat with a bilaterally asymmetrical reproductive tract. J Reprod Fertil (1968) 0.80
Moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol (2008) 0.80
Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol (2005) 0.79
Behavioral effects associated with chronic ketamine or remacemide exposure in rats. Neurotoxicol Teratol (2007) 0.79
An XYY sex-chromosome constitution in the mouse. Cytogenetics (1969) 0.78
Synthetic atrial natriuretic factor decreases renal tubular phosphate reabsorption in rats. Am J Physiol (1985) 0.78
Gastrointestinal Safety Pharmacology in Drug Discovery and Development. Handb Exp Pharmacol (2015) 0.77
Adverse reactions to ginseng. Med J Aust (1981) 0.77
Effect of chronic MK-801 and/or phenytoin on the acquisition of complex behaviors in rats. Neurotoxicol Teratol (2007) 0.77
Regulation of expression of transcobalamin II receptor in the rat. Biochem J (1995) 0.77
Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis (1993) 0.77
Lipopolysaccharide upregulates bradykinin 1 receptors in the isolated mouse bladder. J Urol (1998) 0.77
Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability. J Pharmacol Toxicol Methods (2007) 0.76
Physiopathologic role of cubilin and megalin. Adv Nephrol Necker Hosp (2000) 0.76
Investigation of connexin 43 uncoupling and prolongation of the cardiac QRS complex in preclinical and marketed drugs. Br J Pharmacol (2014) 0.76
Assessing the potential toxicity of MK-801 and remacemide: chronic exposure in juvenile rhesus monkeys. Neurotoxicol Teratol (2002) 0.75
Permeability properties of rat renal lysosomes. Am J Physiol (1994) 0.75
Placement of intraperitoneal injections in rats. Contemp Top Lab Anim Sci (1994) 0.75
Fate of antidiuretic hormone water channel proteins after retrieval from apical membrane. Am J Physiol (1993) 0.75
Effects of eicosanoids on parameters in isolated rat hepatocytes and isolated rat hepatocyte couplets: protective effects of eicosanoid receptor antagonists. J Lipid Mediat Cell Signal (1997) 0.75
[Vesicular flow in epithelial cells: physiopathologic importance of two multiligand receptors]. Bull Acad Natl Med (1997) 0.75
Effect of atrial natriuretic factor on brush border membrane transport of phosphate in phosphate-deprived rats. Biochem Pharmacol (1988) 0.75
Renal autotransplants in sheep: investigation of renal function and renovascular hypertension. Clin Exp Pharmacol Physiol (1982) 0.75
Selected contribution: a three-dimensional model for assessment of in vitro toxicity in balaena mysticetus renal tissue. J Appl Physiol (1985) (2000) 0.75
[Endocytosis and receptors: molecular and physiological aspects]. Nephrologie (1996) 0.75
Primary hyperaldosteronism in pregnancy. Aust N Z J Med (1982) 0.75
FK506-induced endothelin release by cultured rat mesangial cells. J Cardiovasc Pharmacol (1995) 0.75
Effects of converting enzyme inhibition with captopril on renal function in normal and ACTH treated sheep. Clin Exp Pharmacol Physiol (1983) 0.75
Mutagenicity tests with cyclohexylamine in the mouse. Mutat Res (1971) 0.75
Effect of exogenous angiotensin II infusion after one year of captopril therapy in essential hypertension. Postgrad Med J (1986) 0.75
Pneumoperitoneum in peritoneal dialysis patients: significance of diagnosis by CT. J Comput Assist Tomogr (1994) 0.75
Failure of angiotensin II to reduce plasma renin activity in hypertensive pregnant women. J Hypertens Suppl (1984) 0.75
cDNA expression arrays: the effects of lactacystin in lipopolysaccharide-induced cystitis. Urology (2001) 0.75
cDNA array of lipopolysaccharide-induced bladder gene expression. Urology (2001) 0.75